Changes in Beneficial Ownership · 4
Absci Corporation
ABSINASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1782505292.xml
Filing details
- Report period
- 2026-06-24
- Issuer
- Absci Corp
- Issuer CIK
- 0001672688
- Trading symbol
- ABSI
Reporting owner 1
- Name
- McClain Sean
- Reporting owner CIK
- 0001873003
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- C/O ABSCI CORPORATION, 18105 SE MILL PLAIN BLVD, VANCOUVER, WA, 98683
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-24 | F · Form 4 | 59,896[F1] | D | 10.075 | 8,655,555 | D |
Table key
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Amount reported represents the number of shares withheld by the Issuer to cover the tax withholding obligation in connection with the vesting of 150,000 performance-based RSUs upon achievement of a closing stock price equal to or exceeding $10.00 per share, as previously reported in the Reporting Person's Form 4 filed on March 21, 2024, and does not represent a discretionary trade by the Reporting Person.↩ 1
Signature 1
- Signed
- /s/ Shelby Walker, attorney-in-fact
- Date
- 2026-06-26
Company context
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential.